scholarly journals PCN118 Impact of Bone Metastases on Quality of Life in Patients With Castration-Resistant Prostate Cancer (CRPC) at High Risk for Developing Bone Metastases

2012 ◽  
Vol 15 (7) ◽  
pp. A431 ◽  
Author(s):  
G. Hechmati ◽  
J. Arellano ◽  
I. Haynes ◽  
O. Gunther ◽  
A. Worsfold ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
High Risk ◽  
Bone Metastases ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy

Medicine ◽  
2020 ◽  
Vol 99 (38) ◽  
pp. e22287
Author(s):  
Miriam Sraieb ◽  
Nader Hirmas ◽  
Rupert Conrad ◽  
Milka Marinova ◽  
Markus Essler ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Bone Metastases ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

Treatment Given Near the End of Life in Castration-Resistant Prostate Cancer

2012 ◽  
Vol 29 (7) ◽  
pp. 536-540 ◽  
Author(s):  
Hanna A. Zaghloul ◽  
Jose R. Murillo
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
End Of Life ◽  
Treatment Options ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Related Quality ◽  
Impact On Survival ◽  
New Treatments

Chemotherapy treatment options are limited for patients with castration-resistant prostate cancer (CRPC). The purpose of this study is to report treatment use and adverse effects (AEs) within the last three months of life in patients with CRPC. Of the 88 patients identified, 32% received treatment within 3 months of death, and documented AEs occurred in 25% of patients. Of those, neutropenia (18.3%), nausea/vomiting (18.3%), and febrile neutropenia (13.6%) were the most frequent. Results of this study show high treatment utility towards the end-of-life in patients with CRPC, with one fourth of patients experiencing AEs. Attention to health-related quality of life becomes increasingly important as new treatments appear to have small impact on survival, and AEs of those treatments may significantly impact patient quality of life.

Sign in / Sign up

Export Citation Format

Share Document